Status:

COMPLETED

Interleukin (IL)-13 as a Marker in Pediatrics Asthma

Lead Sponsor:

Rush University Medical Center

Conditions:

Asthma

Eligibility:

All Genders

8-15 years

Brief Summary

Asthma is a very common childhood chronic illness and is generally more severe in African Americans. The investigators attempted to determine whether a specific immune marker is associated with lung f...

Detailed Description

This study examined the relationship between Interleukin (IL)-13 from phytohemagglutinin-activated polymorphonuclear blood cells and asthma severity, lung function (measured as FEV1%), and total serum...

Eligibility Criteria

Inclusion

  • African-American race, born in the U.S.
  • Age 8-15 years
  • Clinical diagnosis of asthma
  • Subject is able to understand and follow verbal instructions in English

Exclusion

  • Asthma exacerbation in the 4 weeks preceding the research visit
  • Oral/IV steroid use in the 4 weeks preceding the research visit
  • Upper or lower respiratory tract infection in the 4 weeks preceding the research visit
  • Antibiotic use in the 4 weeks preceding the research visit
  • Use of a short-acting bronchodilator during the 6 hours prior to spirometry (lung function testing)
  • Use of a long-acting bronchodilator during the 12 hours prior to spirometry (lung function testing)

Key Trial Info

Start Date :

November 1 2008

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

August 1 2009

Estimated Enrollment :

19 Patients enrolled

Trial Details

Trial ID

NCT00968305

Start Date

November 1 2008

End Date

August 1 2009

Last Update

August 28 2009

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Rush University Medical Center; Clinic: University Consultants in Allergy and Immunology

Chicago, Illinois, United States, 60612